Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Review and Meta-Analysis of the Safety and Efficacy of Using Glucagon-like Peptide-1 Receptor Agonists
En-Hao Hu, Ming‐Lung Tsai, Yuan Lin, et al.
Medicina (2024) Vol. 60, Iss. 3, pp. 357-357
Open Access | Times Cited: 18

Showing 18 citing articles:

Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease
Aaron A. King, Xi Tan, Neil Dhopeshwarkar, et al.
American Journal of Preventive Cardiology (2025) Vol. 21, pp. 100922-100922
Open Access | Times Cited: 1
Weight Loss Therapies and Hypertension Benefits
Vasiliki Katsi, Eleni Manta, Christos Fragoulis, et al.
Biomedicines (2024) Vol. 12, Iss. 10, pp. 2293-2293
Open Access | Times Cited: 4
Glucagon-like peptide 1 receptor agonists outperform basal insulin in cardiovascular and renal outcomes for type 2 diabetes mellitus: a retrospective cohort study
Tien‐Hsing Chen, Chin-Ju Tseng, Yanrong Li, et al.
Acta Diabetologica (2025)
Closed Access
Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus
Xu He, Wei Zhao, Ping Li, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway
Can Wang, Zhenhua Wu, Jiaying Zhou, et al.
Journal of Cancer Research and Clinical Oncology (2025) Vol. 151, Iss. 3
Open Access
Ketogenic Diets for Body Weight Loss: A Comparison with Other Diets
Damian Dyńka, Łukasz Rodzeń, Mateusz Rodzeń, et al.
Nutrients (2025) Vol. 17, Iss. 6, pp. 965-965
Open Access
Biotechnological Advances in GLP-1 Receptor Agonists: Development, Optimization, and Market Dynamics
Yanze Wang
Highlights in Science Engineering and Technology (2025) Vol. 129, pp. 122-129
Closed Access
Liraglutide Protects Cardiomyocytes against Isoprenaline-Induced Apoptosis in Experimental Takotsubo Syndrome
Zorislava Bajić, Tanja Šobot, Ljiljana Amidžić, et al.
Biomedicines (2024) Vol. 12, Iss. 6, pp. 1207-1207
Open Access | Times Cited: 3
Diabetes, Hypertension and Cardiovascular Disease: Clinical Insights, Mechanisms and Pharmacotherapies
Ming‐Jui Hung
Medicina (2024) Vol. 60, Iss. 4, pp. 566-566
Open Access | Times Cited: 2
Effect of GLP-1RA Treatment on Adhesion Molecules and Monocyte Chemoattractant Protein-1 in Diabetic Patients with Atherosclerosis
Marcin Hachuła, Marcin Basiak, Michał Kosowski, et al.
Life (2024) Vol. 14, Iss. 6, pp. 690-690
Open Access | Times Cited: 2
Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review
Teodor Salmen, Claudia-Gabriela Potcovaru, Cristina Bică, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 10, pp. 1322-1322
Open Access | Times Cited: 1
Effect of GLP-1 receptor agonists on obesity in patients with severe mental illness: A state hospital case series of clozapine-treated patients
Syed Sadat Ali, Narges Ghodsimaab, Matthew Rusling, et al.
Psychiatry Research Case Reports (2024) Vol. 3, Iss. 2, pp. 100231-100231
Open Access
Schilddrüsenkarzinom als potenzielles Risiko bei der Behandlung mit GLP-1-RA?
Kristina Rogal
Info Diabetologie (2024) Vol. 18, Iss. 4, pp. 12-13
Closed Access
As implicações do uso terapêutico de liraglutida em pacientes diabéticos
Carlos Gonzaga Melo Filho, Pedro de Carvalho Figueredo, Letícia Batalha Marinho, et al.
Research Society and Development (2024) Vol. 13, Iss. 8, pp. e8913846569-e8913846569
Open Access
Erhöhen GLP-1-Rezeptoragonisten das Risiko für Schilddrüsenkarzinome?
Kristina Rogal
InFo Hämatologie + Onkologie (2024) Vol. 27, Iss. 10, pp. 30-31
Closed Access
Glucagon-like Peptide 1 Receptor Agonists in Cardio-Oncology: Pathophysiology of Cardiometabolic Outcomes in Cancer Patients
Vincenzo Quagliariello, Maria Laura Canale, Irma Bisceglia, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 20, pp. 11299-11299
Open Access
De la découverte des hormones incrétines aux doubles et triples agonistes GIP / GLP-1 / glucagon
Franck Phan, Romane Bertrand, Chloé Amouyal, et al.
médecine/sciences (2024) Vol. 40, Iss. 11, pp. 837-847
Closed Access
Differential Effects of GLP-1 Receptor Agonists on Cancer Risk in Obesity: A Nationwide Analysis of 1.1 Million Patients
Shauna Levy, Abdallah S. Attia, Rami M. Elshazli, et al.
Cancers (2024) Vol. 17, Iss. 1, pp. 78-78
Open Access
Page 1

Scroll to top